✦ LIBER ✦

Angiosarcoma of the head and neck associated with xeroderma pigmentosum variant

✍ Scribed by De Silva; Nawroz; Doherty

Book ID: 104459134
Publisher: John Wiley and Sons
Year: 1999
Tongue: English
Weight: 962 KB
Volume: 141
Category: Article
ISSN: 0007-0963
DOI: 10.1046/j.1365-2133.1999.02947.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of xeroderma pigmentosum varia

Treatment of xeroderma pigmentosum variant with low-dose etretinate

✍ E. Finkeldstein; A. Lazaroc; S. Halevy 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 663 KB

Cutaneous angiosarcoma of the head and n

Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma

✍ William H. Morrison; Robert M. Byers; Adam S. Garden; Harry L. Evans; K. Kian An 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 880 KB

Genomic structure, chromosomal localizat

Genomic structure, chromosomal localization and identification of mutations in the xeroderma pigmentosum variant (XPV) gene

✍ Yuasa, Mayumi; Masutani, Chikahide; Eki, Toshihiko; Hanaoka, Fumio 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 549 KB

Sclerosing Rhabdomyosarcoma: A Rare Vari

Sclerosing Rhabdomyosarcoma: A Rare Variant With Predilection for the Head and Neck

✍ Thomas A. Knipe; Rakesh K. Chandra; M Frederick Bugg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB

The British Association of Head and Neck

The British Association of Head and Neck Oncologists and British Association of Head & Neck Oncology Nurses Joint Meeting

📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Preoperative radiotherapy and bevacizuma

Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: Two case studies

✍ Bridget F. Koontz; Edward F. Miles; Mary Ann D. Rubio; John F. Madden; Samuel R. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

## Abstract ## Background. Angiosarcoma of the face is a vascular tumor with poor local control and short median survival despite standard treatment. Bevacizumab is a humanized monoclonal antibody to vascular endothelial growth factor (VEGF), which can inhibit tumor growth. It is synergistic with